CLICK HERE if you are a Consumer
Galderma
Roll Over for Important Safety Information

METROGEL® 1%

The One

Topical metronidazole is a frequent choice for the treatment of rosacea. Its efficacy and safety has been reported and confirmed in randomized and controlled clinical trials.

Although the exact mechanism by which metronidazole reduces the inflammatory lesions of rosacea is not fully understood, it is thought that its beneficial effects may result in part from its anti-inflammatory, antimicrobial, and/or anti-oxidant actions.

Because of its water-based gel formulation, MetroGel® 1% is capable of solubilizing a higher concentration of metronidazole (1% vs. 0.75%). MetroGel® 1% also offers several advantages including:

  • Niacinamide decreases transepidermal water loss, participates in the solubilizing process of metronidazole
  • Propylene glycol enhances percutaneous delivery
  • Betadex increases skin permeability
  • No damage to the skin barrier following 2 weeks of treatment (N=25)
Suspension formulations such as creams may be less able to penetrate into the skin. Due to its unique gel formulation, MetroGel® 1% has improved cutaneous permeability, and it protects the skin barrier and curbs transepidermal water loss (TEWL).

HELP YOUR PATIENTS
 FIND A DERMATOLOGIST
(Enter the first 3 digits of your zip code)

Important Safety Information

MetroGel® 1% is indicated for the topical treatment of the inflammatory lesions of rosacea. The following adverse experiences have been reported with the topical use of metronidazole: burning, skin irritation, dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea. MetroGel® 1% gel is contraindicated in individuals with a history of hypersensitivity to metronidazole or any other ingredients in this formulation. For more information about MetroGel®, see Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.